CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): Potential role in HCV-related liver cancer

被引:51
作者
Benkheil, Mohammed [1 ]
Van Haele, Matthias [2 ]
Roskams, Tania [2 ]
Laporte, Manon [1 ]
Noppen, Sam [1 ]
Abbasi, Kayvan [1 ]
Delang, Leen [1 ]
Neyts, Johan [1 ]
Liekens, Sandra [1 ]
机构
[1] Univ Leuven KU Leuven, Rega Inst Med Res, Lab Virol & Chemotherapy, Leuven, Belgium
[2] Univ Leuven KU Leuven, Dept Imaging & Pathol, Translat Cell & Tissue Res, Leuven, Belgium
关键词
Chemokine; Angiogenesis; Hepatocellular carcinoma; Hepatitis C virus; LIGAND; 20; EXPRESSION; INFECTION; RECEPTOR; CELLS; ACTIVATION; PATHWAYS;
D O I
10.1016/j.yexcr.2018.09.023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The CCL20/CCR6 chemokine/receptor axis has previously been shown to contribute to the initiation and progression of hepatocellular carcinoma (HCC) through the recruitment of CCR6-positive leukocytes to the tumor microenvironment. In particular, high serum levels of CCL20 are reported in patients with HCC induced by the hepatitis C virus (HCV). A potential non-immune role for the CCL20/CCR6 axis in HCC development has not yet been investigated. Microarray analysis (Benkheil et al., paper submitted for publication), revealed that CCL20 is highly upregulated in hepatoma cells infected with HCV compared with non-infected hepatoma cells. To determine the role of the CCL20/CCR6 axis in HCV-related HCC, we first explored which cell populations express CCR6 in human liver tissue with chronic disease or HCC. Immunohistochemical (IHC) analysis revealed that CCR6 is present on endothelial cells (ECs) of portal blood vessels in livers with chronic HCV infection and in HCV- and alcoholic-HCC tissue. In addition, we found CCR6 to be expressed on primary macrovascular (HUVECs) and microvascular ECs (HMVEC-ds) where it co-expressed with the endothelial marker CD31. In vitro angiogenesis experiments revealed that CCL20 is a direct pro-angiogenic molecule that induces EC invasion, sprouting and migration through CCR6. Moreover, using the angiogenesis matrigel plug assay in immunodeficient NMRI-nu mice, we clearly showed that CCL20 induces blood vessel formation, by attracting CCR6-positive ECs. Finally, we demonstrated that HCV-induced CCL20 protein expression and secretion in hepatoma cells could be abolished by antiviral treatment, indicating that CCL20 expression is dependent on HCV replication. In contrast to HCV, HBV-infection resulted in a decreased expression of CCL20, implying a virus-specific effect. Taken together, we identified HCV-induced CCL20 as a direct pro-angiogenic factor that acts on endothelial CCR6. These results suggest that the CCL20/CCR6 axis contributes to hepatic angiogenesis, promoting the hypervascular state of HCV-HCC.
引用
收藏
页码:168 / 177
页数:10
相关论文
共 50 条
[41]   Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals [J].
Faillaci, Francesca ;
Marzi, Luca ;
Critelli, Rosina ;
Milosa, Fabiola ;
Schepis, Filippo ;
Turola, Elena ;
Andreani, Silvia ;
Vandelli, Gabriele ;
Bernabucci, Veronica ;
Lei, Barbara ;
D'Ambrosio, Federica ;
Bristot, Laura ;
Cavalletto, Luisa ;
Chemello, Liliana ;
Sighinolfi, Pamela ;
Manni, Paola ;
Maiorana, Antonino ;
Caporali, Cristian ;
Bianchini, Marcello ;
Marsico, Maria ;
Turco, Laura ;
de Maria, Nicola ;
Del Buono, Mariagrazia ;
Todesca, Paola ;
di Lena, Luca ;
Romagnoli, Dante ;
Magistri, Paolo ;
di Benedetto, Fabrizio ;
Bruno, Savino ;
Taliani, Gloria ;
Giannelli, Gianluigi ;
Martinez-Chantar, Maria-Luz ;
Villa, Erica .
HEPATOLOGY, 2018, 68 (03) :1010-1024
[42]   Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy [J].
Sagnelli, Evangelista ;
Stroffolini, Tommaso ;
Sagnelli, Caterina ;
Cacopardo, Bruno ;
Andriulli, Angelo ;
Babudieri, Sergio ;
Coppola, Nicola ;
Gaeta, Giovanni B. ;
Almasio, Piero L. .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 30 (06) :676-681
[43]   Risk factors for liver-related and non-liver-related mortality following a sustained virological response after direct-acting antiviral treatment for hepatitis C virus infection in a real-world cohort [J].
Kozuka, Ritsuzo ;
Tamori, Akihiro ;
Enomoto, Masaru ;
Muto-Yukawa, Yoshimi ;
Odagiri, Naoshi ;
Kotani, Kohei ;
Motoyama, Hiroyuki ;
Kawamura, Etsushi ;
Hagihara, Atsushi ;
Fujii, Hideki ;
Uchida-Kobayashi, Sawako ;
Kawada, Norifumi .
JOURNAL OF VIRAL HEPATITIS, 2023, 30 (05) :374-385
[44]   The Prevalence of Depression and Its Potential Link to Liver Fibrosis in Patients Diagnosed With Chronic Hepatitis C Virus Infection Prior to the Initiation of Direct-Acting Antiviral Treatment [J].
Stoenescu, Andreea Florentina ;
Popescu, Corneliu Petru ;
Florescu, Simin Aysel ;
Vancea, Geta ;
Ceausu, Emanoil ;
Calistru, Petre .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (06)
[45]   Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China [J].
Li, Zhanyi ;
Zhang, Ying ;
Liu, Ying ;
Shao, Xiaoqiong ;
Luo, QiuMin ;
Cai, Qingxian ;
Zhao, Zhixin .
MEDICINE, 2017, 96 (19)
[46]   Rates of sustained virological response 12weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? [J].
Bischoff, J. ;
Mauss, S. ;
Cordes, C. ;
Lutz, T. ;
Scholten, S. ;
Moll, A. ;
Jaeger, H. ;
Cornberg, M. ;
Manns, M. P. ;
Baumgarten, A. ;
Rockstroh, J. K. .
HIV MEDICINE, 2018, 19 (04) :299-307
[47]   Minimal clinically important differences in health-related quality of life after treatment with direct-acting antivirals for chronic hepatitis C: ANRS CO22 HEPATHER cohort (PROQOL-HCV) [J].
Abbas, Mourad ;
Patrizia, Carrieri ;
Fabienne, Marcellin ;
Marc, Bourliere ;
Lucia, Parlati ;
Fabrice, Carrat ;
Martin, Duracinsky ;
Camelia, Protopopescu .
QUALITY OF LIFE RESEARCH, 2024, 33 (06) :1527-1540
[48]   First Case in Kazakhstan of Successful Therapy With 2 Consecutive Direct-Acting Antiviral Regimens in a Patient with Hepatitis C Virus-Induced Decompensated Liver Cirrhosis on a Liver Transplant Wait List [J].
Yesmembetov, Kakharman ;
Ashimkhanova, Aiymkul ;
Kaliaskarova, Kulpash .
EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2016, 14 :112-113
[49]   Metabolic dysfunction in patients following DAAinduced viral cure for HCV infection: A non-negligible risk to liver-related health: Editorial on "Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C" [J].
Liu, Chen-Hua ;
Chang, Yu-Ping .
CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (02)
[50]   Direct-Acting Antivirals Ombitasvir / Paritaprevir / Ritonavir plus Dasabuvir with or Without Ribavirin in Hepatitis C Virus (HCV) Genotype 1-Infected Treatment-Naive or Treatment-Experienced Patients with or Without Cirrhosis: Real-Life Experience in Lithuania and Latvia [J].
Jancoriene, Ligita ;
Polubenko, Katazyna ;
Kazenaite, Edita ;
Buivydiene, Arida ;
Jakutiene, Jolita ;
Tolmane, Ieva ;
Jeruma, Agita ;
Radzisauskiene, Daiva ;
Mockiene, Evelina ;
Ambrozaitis, Arvydas .
HEPATITIS MONTHLY, 2018, 18 (01)